Science
TNFR Superfamily Antagonism with TrapMAbs
BITT’s proprietary TrapMAb monoclonal antibodies target the tumor necrosis factor receptor (TNFR) superfamily via a unique mechanism: they trap nascent TNFR molecules in an inactive hexagonal network.
Compared to conventional monoclonals, these unique antagonists offer an efficacy advantage and, because they are selective for rapidly proliferating cells, TrapMAbs opens the door to TNFR superfamily targets that were previously considered undruggable or limited by toxicology.
